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Food, drug, insect sting allergy, and anaphylaxis
A randomized, double-blind, placebo-controlled study of
milk oral immunotherapy for cow’s milk allergy
Justin M. Skripak, MD,a Scott D. Nash, MD,b Hannah Rowley, RD,a Nga H. Brereton, RD,a Susan Oh, RD,a
Robert G. Hamilton, PhD,a Elizabeth C. Matsui, MD,a A. Wesley Burks, MD,b and Robert A. Wood, MDa Baltimore, Md,
and Durham, NCBackground: Orally administered, food-specific
immunotherapy appears effective in desensitizing and
potentially permanently tolerizing allergic individuals.
Objective: We sought to determine whether milk oral
immunotherapy (OIT) is safe and efficacious in desensitizing
children with cow’s milk allergy.
Methods: Twenty children were randomized to milk or placebo
OIT (2:1 ratio). Dosing included 3 phases: the build-up day
(initial dose, 0.4 mg of milk protein; final dose, 50 mg), daily
doses with 8 weekly in-office dose increases to a maximum of
500 mg, and continued daily maintenance doses for 3 to 4
months. Double-blind, placebo-controlled food challenges; end-
point titration skin prick tests; and milk protein serologic
studies were performed before and after OIT.
Results: Nineteen patients, 6 to 17 years of age, completed
treatment: 12 in the active group and 7 in the placebo group.
One dropped out because of persistent eczema during dose
escalation. Baseline median milk IgE levels in the active (n5 13)
versus placebo (n 5 7) groups were 34.8 kUa/L (range, 4.86–314
kUa/L) versus 14.6 kUa/L (range, 0.93–133.4 kUa/L). The
median milk threshold dose in both groups was 40 mg at the
baseline challenge. After OIT, the median cumulative dose
inducing a reaction in the active treatment group was 5140 mg
(range 2540-8140 mg), whereas all patients in the placebo group
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1154reacted at 40 mg (P 5 .0003). Among 2437 active OIT doses
versus 1193 placebo doses, there were 1107 (45.4%) versus 134
(11.2%) total reactions, with local symptoms being most
common. Milk-specific IgE levels did not change significantly in
either group. Milk IgG levels increased significantly in the
active treatment group, with a predominant milk IgG4 level
increase.
Conclusions: Milk OIT appears to be efficacious in the
treatment of cow’s milk allergy. The side-effect profile appears
acceptable but requires further study. (J Allergy Clin Immunol
2008;122:1154-60.)
Key words: Cow’s milk, food allergy, IgE, prognosis, desensitiza-
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The current standard of care for the management of IgE-
mediated food allergy involves the identification of causative
foods and avoidance of these allergens while always having self-
injectable epinephrine available.1 There are no approved thera-
pies for food allergy, and unfortunately, despite the best efforts
of patients to avoid problem foods, accidental exposures are
very common.2-4 Symptoms associated with these exposures
vary, ranging from mild local reactions to life-threatening
anaphylaxis.5-8
In recent years, orally or sublingually administered allergen-
specific immunotherapy has gained increasing attention. Several
studies have demonstrated that a substantial number of allergic
patients can tolerate gradually increasing amounts of known
allergens, including milk, egg, peanut, and hazelnut.9-17 The re-
sults of these treatments range from protection against small
accidental exposures to the ability to tolerate full servings of
the allergen. However, the majority of these studies have been
small, with limited characterization of patient populations and
dosing protocols. Only one, using sublingual immunotherapy
for hazelnut allergy, has been undertaken with a randomized, pla-
cebo-controlled approach.9 The aim of this study was to further
investigate the safety and efficacy of oral immunotherapy (OIT)
for cow’s milk allergy (CMA) in a randomized, double-blind,
placebo-controlled study of orally administered milk protein in
children with milk allergy.
METHODS
Study design
Children between the ages of 6 and 21 years with a known history of IgE-
mediated milk allergy were recruited from the pediatric allergy clinics at the
Johns Hopkins University Hospital, Baltimore, Maryland, and Duke Univer-
sity Medical Center, Durham, NC. Eligibility criteria were a positive skin
Abbreviations used
CM: Cow’s milk
CMA: Cow’s milk allergy
and the levels (in kUa/L) of IgE, IgG, and IgG4 antibodies specific for cow’s
milk (CM) a-lactalbumin, b-lactoglobulin, and casein by using the Phadia
CAP-System FEIA (Phadia Diagnostics, Uppsala, Sweden). CM IgG and
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prick test (SPT) response to milk extract (wheal  histamine control) or milk
IgE level of greater than 0.35 kU/L and a positive milk challenge result at
baseline defined as reacting with clear signs, symptoms, or both to a
cumulative dose of 2.5 g or less of milk protein. Patients were excluded if
they had a history of anaphylaxis requiring hospitalization, history of
intubation related to asthma, or a current diagnosis of severe persistent asthma.
At the baseline visit, a history and physical examination, pulmonary
function testing, and end-point titration skin prick testing were performed.
Serum was collected for total and milk-specific IgE and IgG antibody
measurements (Fig 1). Participants then returned on 2 separate days for a base-
line double-blind, placebo-controlled food challenge (DBPCFC) to milk. Par-
ticipants meeting all eligibility criteria were then randomized in a 2:1 ratio to
receive active or placebo OIT.
All initial dosing was conducted in the clinical research facility at both
institutions. Milk for active OIT dosing was in the form of dry nonfat
powdered milk. All doses were prepared by the clinical research–registered
dieticians. The immunotherapy dose schedule is outlined in Table I. On the
first day of treatment, a dose escalation was initiated with 0.4 mg of milk pro-
tein. Approximately doubling doses were then given every 30 minutes to a
maximum of 50 mg (cumulative dose, 98.7 mg). Participants had to tolerate
a minimum dose of 12 mg (cumulative dose, 23.7 mg) to proceed with
home dosing.
Home dosing was then initiated at the highest dose tolerated on the dose
escalation day. Premeasured doses were provided to all participants, whowere
instructed to consume 1 dose per day. All were required to have diphenhy-
dramine and self-injectable epinephrine available at all times. Home diary
forms were provided to record the dose date, time taken, symptoms occurring
after the dose or any other time, and medications taken each day. After 7 to 14
days on a given dose, participants returned to the research unit to receive a dose
increase, as described in Table I. Participants who experienced more than a
mild reaction with a home dose were seen in the research unit for their next
dose, which was typically decreased to the previously tolerated dose. Investi-
gators were available 24 hours a day by telephone for questions or
emergencies.
Once a dose of 500 mg (equivalent to 15 mL of milk) was achieved,
participants continued on that dose daily for 13 weeks, after which they
underwent their next DBPCFC. Subjects and investigators were unblinded at
that time, and those who had been receiving placebo were offered the
opportunity to receive open-label active treatment. Subjects receiving active
treatment who tolerated less than 2540 mg in this DBPCFC were returned to
strict milk avoidance, and the others were given detailed instructions for the
continuation of measured amounts of milk protein in their diet based on the
challenge outcome.
Study procedures
End-point titration skin prick testing. End-point titration
skin prick testing was conducted with a commercial milk extract (Greer
Laboratories, Lenoir, NC) diluted with albumin saline with phenol to
concentrations of 1:1, 1:5, 1:10, 1:50, 1:100, 1:1000, 1:10,000, and
1:100,000. Testing was performed with a bifurcated needle. Wheals were
marked with a ballpoint pen and transferred to records with clear adhesive
tape. The most dilute dilution with a wheal at least as large as that elicited by
the histamine control was considered the threshold.
Serology. Blood samples were collected before immunotherapy, when
the maintenance dose was reached, and after completion of immunotherapy.
Serum was analyzed to determine the concentrations (in kIU/L) of total IgEIgG4 levels could not be directly measured because of the presence of interfer-
ing IgG antibodies specific for bovine albumin in most sera. Thus the sum of
the a-lactalbumin–, b-lactoglobulin–, and casein-specific IgG and IgG4 anti-
body levels was used as a surrogate measure of IgG and IgG4 anti-CM anti-
body level. The lower limit of assay detection was 0.35 kU/L for the
specific IgE assay, 2 mg/mL for the specific IgG assays, and 0.1 mg/mL for
the specific IgG4 assays.
DBPCFC. In the baseline challenge milk doses were 40, 100, 400, 800,
and 1200 mg, for a cumulative dose of 2.5 g. The available CM-free vehicles
were applesauce or soymilk or rice milk flavored with chocolate or strawberry
syrup. Either milk powder or placebo powder (Prophree; Abbott Nutrition,
Columbus, Ohio) was mixed with the vehicle and administered at the specified
doses. Challenges were stopped after clear symptoms of an allergic reaction
developed. Emergency medications, including diphenhydramine, epineph-
rine, albuterol, and prednisone were available and administered at the
investigator’s discretion.
Postimmunotherapy food challenges followed the same protocol, with the
addition of 3 more doses of 1600, 2000, and 2000 mg, with a cumulative milk
protein dose of 8 g.
Statistical analysis
Outcomes were evaluated comparing the active and placebo groups.
Results of outcomes for placebo-treated participants who subsequently
received active therapy are shown separately in selected tables and figures
but were not used in the analysis comparing groups.
All analyses were performed with StataSE 8.0 (StataCorp, College Station,
Tex). Categorical data were expressed as proportions and continuous data as
medianswith ranges ormeanswith SDs. Proportions in groupswere compared
by using the Fisher exact test. The Wilcoxon test was used to compare paired
data for end-point titration SPT results, total IgE levels, CM IgE levels, and all
other serologic measurements (in kilounits per liter), comparing the respective
values at baseline with those after treatment. Either the Mann–Whitney test or
the t test was used to compare continuous variables between the 2 groups. A
2-tailedP value of less than .05 was considered statistically significant. Partic-
ipants who had negative SPT responses at all milk extract concentrations were
assigned a threshold concentration value of .1 for the purposes of analysis.
RESULTS
Study population
Twenty patients were enrolled in the study (Table II). Seven-
teen were enrolled at Johns Hopkins Hospital and 3 at Duke Uni-
versity Medical Center. Just over half were male, and the median
age was 9 years among the active-treated and 11 years among the
placebo-treated patients. Most subjects had a past or current
history of eczema, asthma, or both, and three fourths had a history
of at least 1 other food allergy, with a median of 3 other food
allergies. The baseline median milk IgE levels in the active and
placebo groups were 34.8 kUa/L (range, 4.86–314 kUa/L) and
14.6 kUa/L (range, 0.93–133.4 kUa/L), respectively. There
were no significant differences between the active and placebo
groups.
Milk dose threshold
Themedian threshold dose of CM resulting in a reaction was 40
mg in both groups before OIT (Table III and Fig 2). After OIT, the
median change in milk dose threshold was 5100 mg in the active
group (P 5 .002), with no change in the median in the placebo
group (P 5 .16). Among the active treatment group, the range
TABLE II. Demographics of study participants randomized to
active or placebo treatment
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2540 to 8140 mg. All placebo-treated participants reacted at 40
mg (P 5 .0003). Of the 4 participants in the active group to con-
sume the entire 8140 mg, 2 experienced no reaction. Because the
true threshold was unknown based on this challenge, these 2 are
represented in Table III as a threshold of greater than 8140 mg.
The other 2 experienced mild and untreated symptoms at that
maximum dose.
End-point titration SPT threshold
Themedian end-point titration SPT threshold concentrations in
the active group were 1:50 before treatment and 1:3 after
treatment (P 5 .03, Table III and Fig 3). In the placebo group
thresholds were 1:100 before treatment and 1:50 after treatment
(P 5 .03). No statistically significant difference was observed in
the change from baseline between groups (P 5 .12).
Serologic studies
CM-specific IgE antibody results are shown in Table III and Fig
4. Although there was no significant change within any group,
there were several individuals in the active group who exhibited
marked increases. Some returned to baseline by the post-OIT
point, whereas others continued to increase. Although there was
no significant change in CM IgG4 levels in the placebo group,
there was a median increase from baseline of 767% in the active
group (P 5 .002, Table III and Fig 5). CM-specific IgG antibody
levels increased in parallel with the IgG4 antibody levels. This
change from baseline in the active group was statistically
FIG 1. Study timeline. Key features and overall timeframe are shown. OFC,
Oral food challenge.
TABLE I. OIT dosing in milligrams of CM protein
Initial build-up day Every 1 to 2 week dose increases
0.4 75
0.8 100
1.5 130
3 170
6 225
12* 295
25 385
50 500
*Minimum dose tolerated to be taken at home.significant (P 5 .002, data not shown). These increases were
not wholly explained by IgG4 increases, implying that other
IgG subclasses were responsible for some of the increase in the
total CM-specific IgG response. Total serum IgE levels did not
change, on average, but some individuals exhibited increases,
which is similar to CM-specific IgE patterns.
Safety data
The results of dose-related safety measurements during dou-
ble-blind treatment are shown in Table IV. The median number of
doses per participant was 177 in the active group and 171 in the
placebo group, with a total number of 2437 active and 1193
placebo doses.
The median frequency for total reactions in each participant
was 35%, with a wide range of 1% to 95% in the active group
compared with 1% in the placebo group (range, 0% to 53%;
P5 .02). The most common types of reactions in the active group
were local (mostly oral pruritus) and gastrointestinal (mostly ab-
dominal pain), occurring with a median frequency of 16% and 2%
of active doses, respectively (P 5 .006 and .02). One important
note is that of the 458 active doses associated with gastrointestinal
symptoms, 2 participants in the active group accounted for about
two thirds of the reactions with mild abdominal pain that never
required treatment. Reactions involving some combination of
gastrointestinal, lower respiratory tract, and skin symptoms
were categorized as multiple system reactions. These were rare,
occurring with a median frequency of 1% of active doses versus
none in the placebo-treated group (P 5 .01).
Data on treatment of reactions reveals that diphenhydramine
was given with a median frequency of 1% of active doses
compared with 1% of placebo doses. As with the symptom data,
the frequency of diphenhydramine use varied widely in the
active group, from never to 58% of OIT doses. In the active
group one participant who was treated for oral itching accounted
for one third of diphenhydramine doses administered. Four doses
of epinephrine were used to treat reactions in 4 different
participants in the active group; 2 of these occurred with the
initial in-hospital build-up doses, and the other 2 were with home
doses.
There was one participant in each treatment group who
experienced an eczema flare. The placebo group participant’s
flare was managed with topical care along with an oral antibiotic
Characteristics
Active-treated
group (n 5 13)
Placebo-treated
group (n 5 7)
P
value
Male sex, no. (%) 8 (62) 4 (57) 1.0
Age (y), mean (SD) 9.3 (3.3) 10.2 (3.3) .5
Hx/o eczema, no. (%) 7 (54) 4 (57) 1.0
Current eczema, no. (%) 4 (31) 2 (29) 1.0
Hx/o asthma, no. (%) 12 (92) 5 (71) .27
Current asthma, no. (%) 9 (69) 3 (43) .36
Hx/o other FA, no. (%) 10 (77) 5 (71) 1.0
No. of other current FA,
median (range)
2 (0-8) 2 (0-5) .8
Baseline CM IgE (kUA/L),
median (range)
34.8 (4.86-314) 14.6 (0.93-133.4) .19
Hx/o, History of; FA, food allergy.
TABLE III. Outcome data summary
Milk threshold (mg)
End-point titration
SPT (dilution) CM IgE (kU/L) CM IgG4 (mg/mL)
Patient ID no. Age (y) Sex Baseline Posttreatment Baseline Posttreatment Baseline Posttreatment Baseline Posttreatment
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have significant eczema despite aggressive management, which
resulted in her early withdrawal from the protocol while receiving
DISCUSSION
Among young children, CMA is the most common food
allergy, occurring in as many as 2% to 3%.18-21 Although the
Active-treated group
1 6 F 40 >8140 1:100 Negative 9.8 11.4 4.8 68.1
4 6 F 40 4140 1:100 1:100 42 27 3.9 24.4
8 6 M 40 6140 1:5 1:1 20.4 24.1 3 30.1
9 10 M 40 6140 1:100 1:1 30.8 31.1 2.3 23.1
10 12 F 40 2540 1:50 1:10 314 514 5.3 61.7
12 10 M 40 4140 1:10 1:5 84.3 66.2 4.6 33.7
13 7 M 140 8140 1:50 1:100 28.4 26.3 0.3 1.7
14 9 M 40 >8140 1:100 1:1 8.2 7.5 2.4 7.4
15 10 M 40 2540 1:10 1:10 4.9 6.8 1.2 12
17 6 M 140 3140 1:100 1:5 34.8 40 5 17.2
19 15 F 40 NA 1:1 NA 183.2 NA 5.5 NA
23 16 M 140 4140 1:10 Negative 57.5 74.4 18.9 261
25 7 F 1340 8140 1:1 1:1 53.5 26.7 8.3 10.6
Median (range) change 15100 mg (2500- 8100) 5-fold (0-1000) 18% (250-64%) 1767% (29-1321%)
P value .002 .03 NS .002
Placebo-treated group
2 11 F 140 40 1:100 1:100 133.4 119.6 25.4 22.8
3 15 M 40 40 1:10,000 1:1000 36.3 31.4 5.8 5
5 8 F 40 40 1:10 1:1 0.9 1.1 1.4 1.5
6 8 F 40 40 1:100 1:10 3.9 5.5 3 7.7
7 11 M 1340 40 1:100 1:50 28.7 29.9 1.3 2.6
11 6 M 40 40 1:100 1:50 14.4 13.5 1.4 1.6
24 11 M 40 40 1:1000 1:1000 13.5 10.3 1.9 2.9
Median (range) change 0 (21300-0) 2-fold (0-10) 25% (213-71%) 114% (214-157%)
P value NS .03 NS NS
Open label–treated group
2 11 F 40 1340 1:100 1:1 119.6 59.7 22.8 133.5
3 15 M 40 4140 1:100 1:5 31.4 496 5 24.2
5 8 F 40 8140 1:5 Negative 0.9 1 1.5 5.1
6 8 F 40 >8140 1:10 Negative 5.6 2.3 7.7 730
7 11 M 40 >8140 1:50 1:1 29.9 36.9 2.6 16.1
11 6 M 40 8140 1:50 1:5 13.5 10.3 1.6 4.8
Median (range) change 18100 mg (1300-8100) 50-fold (10-100) 26% (259-1480%) 1486% (251-9405%)
P value .02 .03 NS .03
F, Female; M, male; NA, not applicable; NS, not significant.the 225-mg OIT dose.
In general, although reactions were common and all active-
treated patients experienced at least 1 adverse event, nearly 90%
of all acute reactions were transient and required no treatment. It
is also important to note that reactions occurred sporadically at all
dose levels, including during maintenance therapy.
Open label–treated group
Six of the 7 placebo-treated participants elected to receive
open-label active treatment. The milk dose threshold was 40 mg
in all 6 before OIT. After OIT, the median was 8140 mg (range,
1340–8140 mg; P5 .03; Table III and Fig 2). As with the active-
treated blinded group, there was a significant change in SPT
threshold (P 5 .03) and IgG4 levels (P 5 .03). Comparing the
open-label active-treated with the blinded active-treated groups,
there was no significant difference in change from baseline in
any of the SPT, IgE, or IgG antibody measurements.prognosis for CMA resolution had been considered good, with
up to 85% tolerating dairy by the age of 3 years,18,19 more recent
studies show less optimistic outcomes.22-26 Given that milk al-
lergy is extremely prevalent, might be exhibiting an increasing
tendency to persist, is exceedingly difficult to avoid, and has the
potential to result in severe and even fatal reactions,5-8 it is highly
desirable to have some form of therapy to treat this condition.
In this study milk OITwas effective in increasing the threshold
for reactions to milk in all treated children. This study is the first
done in a double-blind, placebo-controlled fashion in children.
before treatment, nearly all individuals had symptoms after the
first 40-mg dose at the baseline food challenge, whereas after
therapy, the average cumulative dose causing a reaction was 5140
mg. The lowest dose causing a reaction in any participant was
1340 mg, which still is likely to be protective against the
overwhelming majority of accidental exposures. However, it is
also important to note that after completion of active treatment,
despite an increased threshold, 14 of 18 still exhibited a reaction
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react to the post-OIT challenge, it is not clear whether they are
fully tolerant or rather transiently desensitized and thus still at risk
of future reactions.
Establishing whether patients are desensitized or tolerized
through OIT is extremely important. Desensitization should be
defined as the ability to tolerate more of an allergenic substance
after treatment. The state of desensitization likely requires
ongoing exposure to be maintained, and it is completely unclear
how long it would take before lack of continued exposure would
result in loss of desensitization. Tolerance should be defined as a
FIG 2. Change in milk dose threshold. A, Threshold change in active group
(P 5 .002). B, Threshold change in placebo group (P 5 .16). Change in
threshold after open-label active treatment in the placebo group is also
shown in Fig 2, B (from after placebo to after milk OIT). Change in threshold
for active versus placebo groups, P 5 .0003. Orange bars represent me-
dians. MOIT, Milk OIT.
FIG 3. Change in end-point titration skin prick testing. A, Threshold change
in active group (P 5 .03). B, Threshold change in placebo group (P 5 .03).
Change in threshold for active versus placebo groups, P 5 .54. Orange
bars represent medians. MOIT, Milk OIT.permanent loss of reactivity to a previously allergenic substance.
This can only be proved by completely removing the relevant
allergen from an individual’s diet for a period of time.
Buchanan et al9 treated 7 patients with 300 mg of egg protein
for 24 months. After treatment, 4 of 7 passed an egg challenge.
These 4 then restricted egg from their diet for 3 to 4 months
and were then rechallenged. Two of the 4 again passed the chal-
lenges, but the other 2 were again reactive and at fairly low
amounts of egg. Whether this represents inadequate therapy or
a subset of patients whowill not be capable of tolerance induction
remains to be determined. Our current study does not address this
FIG 4. Change inmilk-specific IgE levels. Results are shown beforemilk OIT
(MOIT), at maintenance, and after MOIT for the active group (P5 .75;A) and
placebo group (P 5 .46; B). Change in threshold for active versus placebo
groups, P 5 .87. Orange bars represent medians.
FIG 5. Change in milk-specific IgG4 levels. Results are shown before milk
OIT (MOIT), at maintenance, and after MOIT for the active group (P 5 .002;
A) and placebo group (P 5 .6; B). Change in threshold for active versus
placebo groups, P 5 .001. Orange bars represent medians.
TABLE IV. Safety data
Active (n 5 13) Placebo (n 5 7) P value
Doses per child, median (range) 177 (155-242) 171 (152-199) .05
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tinuing with daily consumption of dairy as instructed.
With regard to other outcomes, although there were many
highly significant increase in hazelnut tolerance in the actively
treated group. Five of 11 in the active group compared with
1 of 11 in the placebo group were able to tolerate the entire 20
Total doses 2437 1193 NA
Symptom/treatment No. (%) of total doses
Percentage of doses with
reaction/treatment per
child, median
(range) No. (%) of total doses
Percentage of doses with
reaction/treatment per
child, median
(range)
Total reactions 1107 (45.4) 35 (1-95) 134 (11.2) 1 (0-53) .02
Local symptoms 870 (35.7) 16 (1-90) 104 (8.7) 1 (0-53) .006
Gastrointestinal 458 (18.7) 2 (0-93) 16 (1.3) 0 (0-3) .02
Lower respiratory 198 (8.1) 1 (0-82) 28 (2.3) 1 (0-12) .3
Skin 22 (0.9) 0 (0-8) 1 (0.1) 0 (0-1) .1
Multiple systems 29 (1.2) 1 (0-7) 0 0 .01
Eczema flare 1 patient NS 1 patient NS NS
Diphenhydramine 249 (10.2) 1 (0-58) 14 (1.1) 1 (0-6) .3
Albuterol 21 (0.9) 0 (0-4) 2 (0.2) 0 (0-1) .2
Epinephrine 4 (0.2) 0 (0-1) 0 0 .1
NA, Not applicable; NS, not significant.actively treated participants with large changes in the end-point
titration SPT threshold, the median change was not statistically
different than that with placebo. It did appear that larger fold
changes were associated with higher milk dose thresholds, but
this could not be confirmed statistically in this small group. Milk-
specific IgE antibody levels remained unchanged, on average,
after 3 or 6 months of treatment. In previous studies, significant
decreases in food-specific IgE levels have been reported at time
points ranging from 6 to 24 months of therapy.9,11,14,17 It is pos-
sible that the duration of treatment in our study was not long
enough to see a decrease in serum IgE antibody levels. It appeared
that higher baseline milk-specific IgE levels were associated with
lower post-OIT milk dose thresholds, as well as with greater dif-
ficulty in tolerating milk OIT doses, but like the SPT results, this
could not be confirmed statistically in this small group.
Milk-specific IgG4 antibody levels exhibited a large increase
by the 3-month time point in the actively treated group. Possibly
because of sample size, there was no apparent association
between the degree of increase in milk-specific IgG4 level and
the observed clinical outcome. However, there was large individ-
ual variability such that large increases in milk-specific IgG4
antibody levels did not guarantee significantly higher milk
thresholds and smaller increases did not exclude higher
thresholds.
There are a number of recent reports in the literature of food-
specific OIT, including that to milk, egg, peanut, hazelnut, and
fish.10-17 However, these reports have varied widely using differ-
ent modes of delivery (sublingual versus oral/swallowed), widely
differing dosing regimens, and variable criteria to define out-
comes. In a recent study of OIT by Longo et al,11 children with
severe milk allergy were gradually escalated to a goal of 5 ounces
of milk. After 1 year, one third could tolerate this amount or more,
one half tolerated between 1 teaspoon and 5 ounces, and 10% dis-
continued treatment because of side effects.
In contrast, Enrique et al10 reported on the use of hazelnut sub-
lingual immunotherapy. These patients were escalated to a main-
tenance dose in 4 days and treated for 5 months. There was ag of hazelnut at the posttreatment challenge. However, approxi-
mately half of the active-treated participants had a history de-
scribed as only oral allergy syndrome. Minimal dose-related
systemic side effects were reported, and there were no dropouts.
The studies by Longo et al11 and Enrique et al10 are representative
of the variability in study populations and methodologies used in
oral food-specific immunotherapy protocols.
In our study adverse reactions were common, but the risk of a
severe reaction fell within the range that we would consider
acceptable. Despite the relatively high frequency of reactions of
any type (45% of active doses), nearly 90% were transient
reactions that required no treatment. Approximately 1 in 100
active doses resulted in a multisystem reaction, and 1 in 600
resulted in a reaction requiring treatment with epinephrine.
Although the ideal for any therapy is no serious reactions, when
dealing with highly allergic children, some level of reaction is
almost inevitable. It is essential that families considering OIT
trials be made aware of these risks, that emergency medications
are always available, and that physician coverage be available at
all times. Families contemplating such therapy will need to
consider whether the benefit of increased, but not necessarily
complete, tolerance is worth these risks compared with the
alternative of strict avoidance. The majority of prior studies
involving orally administered immunotherapy reported less fre-
quent reactions either of a mild or more serious nature.10,12-17
Only Longo et al11 reported the need for intramuscular epineph-
rine, and this was only with in-hospital rapid build-up. This con-
trasts with our experience, in which local symptoms were
common in most individuals. Although there was a tendency
for symptoms to be more common during build-up, they were still
observed duringmaintenance, even including 1 reaction requiring
epinephrine. Possible explanations for these discrepancies could
be that our study population was on average more severely aller-
gic, that our subjects were more diligent in reporting symptoms,
that we did not require maintenance oral antihistamines as has
been done in some other studies,11,12 and/or that our dosing pro-
tocol was not optimal.
Another issue regarding safety is what appear to be factors
associated with a lower threshold for reaction to OIT. This
concept was previously raised by Staden et al,17 who referred to
6. Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions
to foods. J Allergy Clin Immunol 2001;107:191-3.
7. Pumphrey RS, Gowland MH. Further fatal allergic reactions to food in the United
Kingdom, 1999-2006. J Allergy Clin Immunol 2007;119:1018-9.
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this, it is our impression from this study that both exercise and
infectious illnesses can potentially contribute to a reaction at a
previously well-tolerated OIT dose.
Future studies should be aimed at improving both the safety
and efficacy of this form of treatment. It is possible that smaller
incremental increases in doses might lessen reaction frequency or
severity. However, because there was no clear preponderance of
reactions at or shortly after dose increases, this might not be the
case. It is also possible that treatment through the sublingual
route, which might allow for much lower doses, would be better
tolerated. Having all participants take a daily long-acting anti-
histamine might help to reduce mild symptoms.
In conclusion, this study provides evidence that orally admin-
istered immunotherapy can result in a significant degree of
desensitization to a given food in most allergic patients. Although
allergic reactions to OIT doses were common, the majority did
not require treatment, and reactions that did require treatment
responded well to medications administered by parents. Future
studies should aim to establish optimal doses, length of therapy,
and route of therapy (oral/swallowed vs sublingual) required to
obtain maximal desensitization. Once this is established, further
investigation of whether this treatment can induce long-term
tolerance or just temporary desensitization will be essential.
Finally, given the current uncertainty regarding both safety and
efficacy, it is essential that these clinical trials be completed
before anyone considers the use of OIT in clinical practice.
Clinical implications: Milk OIT is effective in desensitizing
allergic children. Further studies are needed to clarify optimal
dosing and duration of therapy, determine whether permanent
tolerance is achievable, and reduce adverse reactions.
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